It’s been one of the hottest biotechs we’ve bought over the last five years…
Since recommending ACADIA Pharmaceuticals (ACAD) at $1.05 and $1.24 in 2010, we’ve watched the stock soar to $51.99 for gains of 4,851% and 4,093%.
Every $1,000 risked is now worth well over $45,000.
Every $5,000 risked is now well over $230,000.
Those are life-changing returns. We can’t overlook that.
What’s interesting is the run, in our opinion, is far from over. Just weeks after an FDA advisory panel committee green-lighted the company’s Parkinson’s disease Psychosis (PDP) drug, it now heads to the FDA for approval.
Once approved, this PDP drug could help millions that suffer from the debilitating disease, perhaps adding billions to ACAD’s bottom line. Considering there are no other FDA-approved drugs on market to treat PDP, you can see why we’re so excited.
Unbelievably, much of Wall Street ignored this stock at such lows. We didn’t, though, because we saw value where others did not.